← Back to Search

Rho kinase inhibitor and Prostaglandin analogue

Rocklatan for Glaucoma

Phase 4
Waitlist Available
Research Sponsored by Aerie Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (day 0 pretreatment), week 12
Awards & highlights
Drug Has Already Been Approved
No Placebo-Only Group
Pivotal Trial

Summary

This trial is testing if Rocklatan can better lower eye pressure in patients who are already using latanoprost-based treatments. Rocklatan works by helping fluid drain from the eye more effectively.

Eligible Conditions
  • Glaucoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (day 0 pretreatment), week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (day 0 pretreatment), week 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Mean Percent Change From Baseline in Intraocular Pressure (IOP) at Week 12

Side effects data

From 2023 Phase 4 trial • 136 Patients • NCT05283395
20%
Conjunctival hyperaemia
3%
Femur fracture
100%
80%
60%
40%
20%
0%
Study treatment Arm
Rocklatan (Latanoprost +2)
Rocklatan (Latanoprost +1)
Rocklatan (Latanoprost Mono)

Awards & Highlights

Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

1Treatment groups
Experimental Treatment
Group I: RocklatanExperimental Treatment1 Intervention
Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution, one drop in each eye in the evening for 12 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution
2022
Completed Phase 4
~140

Find a Location

Who is running the clinical trial?

Aerie PharmaceuticalsLead Sponsor
38 Previous Clinical Trials
8,190 Total Patients Enrolled
25 Trials studying Glaucoma
6,269 Patients Enrolled for Glaucoma
Scientific Advisor, Clinical R&DStudy DirectorAlcon Research, LLC
Michelle S Senchyna, PhDStudy DirectorAerie Pharmaceuticals
1 Previous Clinical Trials
40 Total Patients Enrolled
~38 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top